5.61
Schlusskurs vom Vortag:
$5.50
Offen:
$5.43
24-Stunden-Volumen:
1.10M
Relative Volume:
0.86
Marktkapitalisierung:
$763.89M
Einnahmen:
$62.04M
Nettoeinkommen (Verlust:
$-533.34M
KGV:
-1.4311
EPS:
-3.92
Netto-Cashflow:
$-473.07M
1W Leistung:
+0.72%
1M Leistung:
-19.05%
6M Leistung:
-26.67%
1J Leistung:
-29.43%
Vir Biotechnology Inc Stock (VIR) Company Profile
Firmenname
Vir Biotechnology Inc
Sektor
Branche
Telefon
415-906-4324
Adresse
1800 OWENS STREET, SAN FRANCISCO, CA
Vergleichen Sie VIR mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
VIR
Vir Biotechnology Inc
|
5.61 | 763.89M | 62.04M | -533.34M | -473.07M | -3.92 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Vir Biotechnology Inc Stock (VIR) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2024-01-29 | Herabstufung | JP Morgan | Overweight → Neutral |
2023-09-08 | Herabstufung | BofA Securities | Buy → Neutral |
2023-03-06 | Hochstufung | JP Morgan | Neutral → Overweight |
2023-02-21 | Hochstufung | Goldman | Neutral → Buy |
2023-01-27 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
2022-09-14 | Eingeleitet | SVB Leerink | Outperform |
2022-09-09 | Eingeleitet | Morgan Stanley | Underweight |
2022-03-03 | Hochstufung | Robert W. Baird | Underperform → Neutral |
2021-12-21 | Herabstufung | Robert W. Baird | Neutral → Underperform |
2021-10-25 | Hochstufung | JP Morgan | Underweight → Neutral |
2021-09-22 | Herabstufung | Goldman | Buy → Neutral |
2021-06-04 | Fortgesetzt | Robert W. Baird | Neutral |
2021-01-27 | Herabstufung | JP Morgan | Neutral → Underweight |
2021-01-20 | Bestätigt | H.C. Wainwright | Buy |
2020-10-05 | Eingeleitet | BofA Securities | Buy |
2020-09-14 | Hochstufung | Goldman | Neutral → Buy |
2020-09-11 | Hochstufung | JP Morgan | Underweight → Neutral |
2020-08-20 | Eingeleitet | Needham | Buy |
2020-03-19 | Herabstufung | JP Morgan | Neutral → Underweight |
2020-03-13 | Herabstufung | Goldman | Buy → Neutral |
2020-02-27 | Herabstufung | Robert W. Baird | Neutral → Underperform |
2020-02-04 | Herabstufung | JP Morgan | Overweight → Neutral |
2019-11-14 | Eingeleitet | Robert W. Baird | Neutral |
2019-11-05 | Eingeleitet | Barclays | Overweight |
2019-11-05 | Eingeleitet | Cowen | Outperform |
2019-11-05 | Eingeleitet | Goldman | Buy |
2019-11-05 | Eingeleitet | JP Morgan | Overweight |
Alle ansehen
Vir Biotechnology Inc Aktie (VIR) Neueste Nachrichten
When (VIR) Moves Investors should Listen - news.stocktradersdaily.com
5 Analysts Have This To Say About Vir Biotechnology - Benzinga
Lobbying Update: $50,000 of VIR BIOTECHNOLOGY INC. lobbying was just disclosed - Nasdaq
Vir Biotechnology, Inc. (VIR): Among Stocks Under $10 that Will Triple - Insider Monkey
10 Stocks Under $10 that Will Triple - Insider Monkey
Vir Biotechnology CEO Marianne de Backer sells $474,238 in stock By Investing.com - Investing.com South Africa
Vir Biotechnology CEO Marianne de Backer sells $474,238 in stock - Investing.com
Vir Biotechnology CEO Sells Shares to Cover Tax Obligations - TradingView
Vir Biotechnology stock hits 52-week low at $6.07 By Investing.com - Investing.com Australia
Vir Biotechnology stock hits 52-week low at $6.07 - Investing.com
Vir Biotechnology, Inc. (NASDAQ:VIR) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Vir Biotechnology Insiders Sell US$1.3m Of Stock, Possibly Signalling Caution - simplywall.st
Vir Biotechnology, Inc. (NASDAQ:VIR) is favoured by institutional owners who hold 53% of the company - Yahoo
Vir Biotechnology stock hits 52-week low at $6.54 By Investing.com - Investing.com South Africa
Vir Biotechnology stock hits 52-week low at $6.54 - Investing.com India
(VIR) Trading Advice - news.stocktradersdaily.com
Brii Biosciences Provides Corporate Update and Reports Full-Year 2024 Financial Results - Quantisnow
Hepatitis D Pipeline 2025: MOA and ROA Insights, Clinical Trials - openPR.com
(VIR) Trading Signals - Stock Traders Daily
Morgan Stanley maintains $20 target on Vir Biotechnology stock By Investing.com - Investing.com Canada
Morgan Stanley maintains $20 target on Vir Biotechnology stock - Investing.com India
Vir Biotechnology enrolls first patient in late-stage study of its treatment for severe liver infection - Marketscreener.com
Vir Biotechnology Enrolls First Patient in Phase 3 Chronic Hepatitis Delta Trial -March 13, 2025 at 08:30 am EDT - Marketscreener.com
Vir Biotechnology Enrolls First Patient in Phase 3 ECLIPSE Registrational Program for Chronic Hepatitis Delta - Business Wire
Insider Sell: Vicki Sato Sells Shares of Vir Biotechnology Inc (VIR) - GuruFocus
SBI Securities Co. Ltd. Invests $60,000 in Vir Biotechnology, Inc. (NASDAQ:VIR) - Defense World
Brokerages Set Vir Biotechnology, Inc. (NASDAQ:VIR) Price Target at $35.67 - Defense World
Vir Biotechnology price target raised to $14 from $10 at JPMorgan - MSN
Principal Financial Group Inc. Has $3.28 Million Stake in Vir Biotechnology, Inc. (NASDAQ:VIR) - Defense World
Vir Biotechnology, Inc. (NASDAQ:VIR) Shares Purchased by New York State Common Retirement Fund - Defense World
Rhumbline Advisers Has $1.74 Million Stock Position in Vir Biotechnology, Inc. (NASDAQ:VIR) - Defense World
Vir Biotechnology: Catalysts Ahead In Hepatitis And Oncology (NASDAQ:VIR) - Seeking Alpha
Vir Biotechnology's (VIR) Buy Rating Reiterated at Needham & Company LLC - MarketBeat
What is HC Wainwright’s Forecast for VIR Q1 Earnings? - Defense World
(VIR) On The My Stocks Page - Stock Traders Daily
HC Wainwright Reaffirms “Buy” Rating for Vir Biotechnology (NASDAQ:VIR) - Defense World
Vir Biotechnology’s Strategic Advancements and Financial Health Justify Buy Rating - TipRanks
Vir Biotechnology (NASDAQ:VIR) Stock Price Expected to Rise, Barclays Analyst Says - Defense World
Analysts Have Lowered Expectations For Vir Biotechnology, Inc. (NASDAQ:VIR) After Its Latest Results - Yahoo Canada Finance
7 Analysts Have This To Say About Vir Biotechnology - Benzinga
Decoding Vir Biotechnology Inc (VIR): A Strategic SWOT Insight - GuruFocus.com
Vir Biotechnology’s Transformative Year: Earnings Call Insights - TipRanks
Vir Biotechnology Becomes Oversold (VIR) - Nasdaq
Vir Biotechnology EVP vanina de Verneuil sells $67,402 in stock By Investing.com - Investing.com Canada
Vir Biotechnology EVP vanina de Verneuil sells $67,402 in stock - Investing.com India
Vir Biotechnology, Inc. (NASDAQ:VIR) Q4 2024 Earnings Call Transcript - Insider Monkey
Finanzdaten der Vir Biotechnology Inc-Aktie (VIR)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):